Allergan plc, AGN is in the exchange NYSE and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Allergan plc, AGN has a market cap of 91408.21. Since its IPO date on the 2/17/1993, Allergan plc, AGN performance year to date is -25.11%. Today Allergan plc, AGN has gained 0.14%, with a current price of 234.34.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 89.80%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at *TBA, with return on investment at -1.30%.
In terms of debt levels and profit levels, Allergan plc, AGN is seeing a long-term debt/equity of 0.53. While Total debt/equity is 0.59. With a profit margin of *TBA, this is combined with a gross margin of 71.80%, and operating margin of *TBA. Allergan plc ability to meet debt levels, with a current ratio of 1, while the quick ratio is 0.9.
For the last year Allergan plc, AGN has seen a EPS growth of 23.00%. A performance for the year of -23.90%. The 52-week high is -31.15%, and the 52-week low is 19.87%. The average volume for Allergan plc, AGN is 1031707.
With a target price of 293.06, can Allergan plc, AGN reach this target? Looking at the value indicators of Allergan plc, AGN. Allergan plc has a P/E of *TBA and a forward P/E of 13.49. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Allergan plc also has a P/S and a P/B of 5.61 and 1.27 respectively. For P/cash, Allergan plc has a value of 40.2, while it is *TBA for P/free cash flow.
At the current price of 234.34, Allergan plc has a dividend yield of 0.09%. We see a return on equity of *TBA.
Looking more long-term Allergan plc, is projected to get an EPS growth for the next five years of 9.70%. In the short-term an EPS growth of 22.02% in the next year is forecasted. This is after a EPS growth of 23.00% for this year and for the last five years a -50.40% growth has been seen.